Telepsychiatry in 2026: How Virtual Mental Health Care Actually Works
Mental health is telehealth's highest-volume category. What telepsychiatry covers well, the DEA controlled substance rules for stimulants, and the GLP-1 psychiatric intersection.
Mental health is the single largest telehealth category by visit volume — and telepsychiatry (psychiatric medication management) has been one of the most impactful expansions. For patients managing depression, anxiety, ADHD, or other psychiatric conditions, understanding what telepsychiatry can and can't do is essential for using it effectively.
What telepsychiatry covers well
- Medication management for established diagnoses: follow-up prescribing and dose adjustment for patients with known conditions on stable regimens — highly telehealth-compatible
- Initial evaluation for common conditions: depression, generalized anxiety, ADHD in adults can be assessed via synchronous video with a psychiatrist or psychiatric NP
- Medication initiation for appropriate candidates: SSRIs, SNRIs, non-stimulant ADHD medications, and many other psychiatric medications can be prescribed via telehealth
Stimulant ADHD medications (Adderall, Ritalin, Vyvanse) and benzodiazepines are Schedule II/IV controlled substances. During COVID, DEA temporary rules allowed telehealth prescribing for these without an in-person visit. The Ryan Haight Act exception expires periodically and requires renewal. As of mid-2026, DEA regulations require an in-person visit OR a specific telehealth prescribing platform registration for stimulant prescribing — verify current rules before initiating.
The GLP-1 and mental health intersection
GLP-1 medications have generated psychiatric questions in both directions: case reports of mood changes (in either direction) on GLP-1 treatment, and increasing interest in GLP-1 effects on addiction and substance use (the alcohol cravings signal has received substantial research attention). For patients on GLP-1s experiencing mood changes, telepsychiatry provides a low-barrier evaluation pathway that doesn't require stopping the GLP-1 while the evaluation proceeds.
Verified telehealth providers
Mental health and psychiatric telehealth. Same-day availability.
Paid link Get started →